Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
rAAV-sPD1-TWIST1
- Development stage
- Preclinical
- Lead developer
- National Taiwan University
- Modality
- Gene Therapies
- Administration
- Intratumoral, Intramuscular
01
Overview
rAAV-sPD1-TWIST1 is a recombinant adeno-associated virus (rAAV)-vectored gene therapy candidate encoding a fusion protein composed of soluble programmed cell death protein 1 (sPD1) and the TWIST1 antigen. This unique construct delivers simultaneous immune checkpoint blockade via persistent sPD1 production and enhanced antigen-specific T cell responses through vaccination against the tumor-associated antigen TWIST1. The therapy is designed primarily for the treatment of malignant mesothelioma and potentially other TWIST1-expressing tumors, acting through a combination of immune activation, checkpoint inhibition, and local oncosuppression. In preclinical models, rAAV-sPD1-TWIST1 administered intratumorally led to the eradication of established mesothelioma by activating TWIST1-specific cytotoxic T lymphocytes and enhancing immune infiltration into tumors[1][2][5].
- Brand names
- rAAV-sPD1-TWIST1rAAV-sPD-1-TWIST1rAAV-sPD 1-TWIST1
- Other names
- rAAV-sPD1-TWIST1rAAV-sPD-1-TWIST1rAAV-sPD 1-TWIST1
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)TWIST1
Beyond the preview
Go deeper on rAAV-sPD1-TWIST1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on rAAV-sPD1-TWIST1.